RECORDATI d?signe un nouveau Directeur G?n?ral pharmaceutique en Italie

Milan, le 29 août 2006 – Recordati a annoncé la nomination du Dr. Andrea Breschi dans le poste de Directeur Général Pharmaceutique Italie. Le Dr. Breschi, de 48 ans, né à Pérouse (Italie) et diplômé en Médecine, possède une expérience de vingt ans dans le secteur pharmaceutique aussi bien en Italie qu'à l'étranger. Depuis 2001, il occupait le poste de Directeur Général de Malesci S.p.A., société du groupe Menarini.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,000. A European field force of over 1,000 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2005 was € 576.1 million, operating income was € 111.1 million and net income was € 64.5 million.

For further information:

Recordati website: www.recordati.com

Investor Relations
Marianne Tatschke
(39)0248787393
e-mail: [email protected]

Media Relations
Claudio Rossetti (Echo Comunicazione d'Impresa)
(39)02 62694736
e-mail: [email protected]